| abstract |
This invention relates to a new polymorph V of torasemide, to a method for its preparation, to its use as a raw material for the preparation of crystalline modifications of I and III of torasemide, to amorphous modifications of torasemide and to pharmaceutically acceptable salts of torasemide, to pharmaceutical forms containing the specified new polymorph V of torasemide as an active ingredient, as well as their use. |